Major clinical trial pits proton versus photon radiotherapy in prostate cancer

The national 3000-patient COMPPARE trial, which is examining outcomes with proton versus photon radiotherapy in prostate cancer, continues its robust enrollment at more than 50 clinical sites.¹

Both forms of therapy are considered standard of care in prostate cancer; however, some data suggest that proton therapy may offer a safer alternative without sacrificing efficacy.² The safety difference may arise because while photon therapy delivers X-rays that go through the tumor, potentially damaging nearby healthy tissue, proton therapy transmits proton particles that stop directly at the tumor, sparing healthy cells.

Read the full article here.